IVERMECTIN IN THE TREATMENT OF COVID-19 DISEASE: A SYSTEMATIC REVIEW AND META-ANALYSIS

Authors

  • DEWA AYU AGUS SRI LAKSEMI Department of Parasitology, Faculty of Medicine, Udayana University, Jalan PB Sudirman Denpasar, Bali 80234, Indonesia https://orcid.org/0000-0001-5579-5531
  • I. KETUT TUNAS Health Information Management Studi Program, Bali International University Jl. Seroja, Gang Jeruk, Kelurahan Tonja Denpasar Utara, Bali 80239, Indonesia
  • PUTU EKA WIDYADHARMA Department of Neurology, Faculty of Medicine, Udayana University, Jalan PB Sudirman Denpasar, Bali 80234, Indonesia https://orcid.org/0000-0002-4554-0348
  • WAYAN GDE ARTAWAN Department of Preventive Medicine and Public Health, Faculty of Medicine, Udayana University, Jalan PB Sudirman Denpasar, Bali 80234, Indonesia https://orcid.org/0000-0002-8173-9311
  • LUH PUTU RATNA SUNDARI Physiology Department, Faculty of Medicine, Udayana University Jalan PB Sudirman Denpasar, Bali 80234, Indonesia

DOI:

https://doi.org/10.22159/ijap.2022v14i4.44689

Keywords:

COVID-19, Ivermectin, Treatment, Meta-analysis

Abstract

Objective of the review was to evaluate the effectiveness of Ivermectin as a treatment of COVID-19. The researchers collected and assessed articles and previous studies in the form of Randomized Clinical Trial (RCT) from PubMed, Google Scholar, Clinical Trials Gov and Preprint databases. The inclusion criteria of the study were the patients diagnosed with mild to moderate COVID-19 who had only been given Ivermectin compared to placebo or Standard of Cure (SoC) of COVID-19. There are 11 RCT which are resemble to the inclusion criteria of the study. Based on the 11 RCT that are suitable to the inclusion criteria of the study, the researchers found the pooled OP rate for viral load, Day to Negativity (DTN), and Escalation of Cure for all studies are 62% (95% CI, 0.50-0.74), 89% (95% CI, 0.40-1.38) and 43% (95% CI, 0.06-0.08) respectively. Moreover, the pooled OR rate for length of stay or hospitalization, mortality or deterioration, symptom reduction of all studies are 100.6% (95% CI, 0.54-1.58). Due to the lack of substantial data on information sources and low-to-moderate quality of studies which are included in systematic review, the evidence suggests that IVM (Ivermectin) administration does not decrease the mortality, symptom and viral load of COVID-19.

Downloads

Download data is not yet available.

References

Michael and Ramatillah DL. Treatment profile and survival analysis acute respiratory distress syndrome (ARDS) COVID-19 patients. Int J Appl Pharm. 2022; 14(2):54–56. doi: 10.22159/ijap.2022.v14s2.44750

Tunas IK, Sri Laksemi DAA, Widyadharma IPE, Sundari LPR. The efficacy of covid-19 vaccine and the challenge in implementing mass vaccination in Indonesia. Int J App Pharm 2021; 13(4):1-3. doi:10.22159/ijap.2021v13i4.41270

Sreedevi A, Retna AM, Samuel RK. Molecular docking study of naturally occurring compounds as inhibitors of COVID -19. Asian J Pharm Clin Res 2021, 15, 69-71. doi: 10.22159/ajpcr.2022.v15i1.43121

Kumari VBC, Patil SM, Shirahatti PS, Sujay Y, Tejaswini M, Ranganatha LV, Jayanthi MK, Ramu R. The current status and perspectives for the emerging pandemic: COVID-19. Int J Pharm Pharm Sci 2020, 12, 1-10. doi:10.22159/ijpps.2020v12i8.38206Yavuz S, Ünal S. Antiviral treatment of COVID-19. Turk J Med Sci 2020; 50(SI-1):611-619. doi: 10.3906/sag-2004-145.

Laksemi DA, Sukrama DM, Sudarmaja M, Damayanti PA, Swastika K, Diarthini NLP, Astawa NM, Tunas K. Medicinal plants as recent complementary and alternative therapy for COVID-19: A Review. Trop J Nat Prod Res 2020; 4(12):1025-1032. doi:10.26538/tjnpr/v1i4.5

Dawoud DM, Soliman KY. Cost-Effectiveness of antiviral treatments for pandemics and outbreaks of respiratory illnesses, including COVID-19: A systematic review of published economic evaluations. Value Health 2020 ;23(11):1409-1422. doi: 10.1016/j.jval.2020.07.002.

Ahmed S, Karim MM, Ross AG, Hossain MS, Clemens JD, Sumiya MK, Phru CS, Rahman M, Zaman K, Somani J, Yasmin R, Hasnat MA, Kabir A, Aziz AB, Khan WA. A five-day course of ivermectin for the treatment of COVID-19 may reduce the duration of illness. Int J Infect Dis. 2021 Feb;103: 214-216. doi: 10.1016/j.ijid.2020.11.191.PMID: 33278625

Garcia PJ, Mundaca H, Ugarte-Gil C, Leon P, Malaga G, Chaccour C, Carcamo CP. Randomized clinical trial to compare the efficacy of ivermectin versus placebo to negativize nasopharyngeal PCR in patients with early COVID-19 in Peru (SAINT-Peru): a structured summary of a study protocol for randomized controlled trial. Trials. 2021 Apr 9;22(1):1-3. doi: 10.1186/s13063-021-05236-2. PMID: 33836826

Sharun K, Dhama K, Patel SK, Pathak M. Ivermectin, a new candidate therapeutic against SARS-CoV-2/COVID-19. Ann Clin Microbiol 2020;23(2020):1-5. doi: 10.1186/s12941-020-00368-w. PMID: 32473642

Barrows NJ, Campos RK, Powell ST, Prasanth KR, Schott-Lerner G, Acosta R S, Muñoz GG, McGrath EL, Garza RU 4, Gao J, Wu P, Menon R, Saade G, Salas IF, Rossi SL, Vasilakis N, Routh A, Bradrick SS, Blanco MAG. A screen of FDA-approved drugs for inhibitors of zika virus infection. Cell Host Microbe 2016;20(2):259–70. doi: 10.1016/j.chom.2016.07.004

Caly L, Druce JD, Catton MG, Jans DA, Wagstaff KM.The FDA-approved drug ivermectin inhibits the replication of SARS-CoV-2 in vitro. Antiviral Res 2020; 178(2020): 1-4. doi:10.1016/j.antiviral.2020.104787.

Babalola OE, Bode CO, Ajayi AA, Alakaloko FM, Akase IE, Otrofanowei E, Salu OB, Adeyemo WL, Ademuyiwa AO, Omilabu S. Ivermectin shows clinical benefits in mild to moderate COVID19: A randomised controlled double-blind, dose-response study in Lagos. Q J Med 2022; 114 (11): 780-788. doi: 10.1093/qjmed/hcab035. PMID: 33599247.

Abd-Elsalam S, Noor RA, Badawi R, Khalaf M, Esmail ES, Soliman S, El Ghafar SA, Elbahnasawy M, Moustafa EF, Hassany SM, Medhat MA, Ramadan HKA, Eldeen MAS, Alboraie M, Cordie A, Esmat G. Clinical study evaluating the efficacy of ivermectin in COVID-19 treatment: A randomized controlled study. J Med Virol 2021;93(10):5833-5838. doi: 10.1002/jmv.27122.

Chaccour C, Casellas A, Blanco-Di Matteo A, Pineda I, Fernandez-Montero A, Ruiz-Castillo P, Richardson MA, Rodríguez-Mateos M, Jordán-Iborra C, Brew J, Carmona-Torre F, Giráldez M, Laso E, Gabaldón-Figueira JC, Dobaño C, Moncunill G, Yuste JR, Del Pozo JL, Rabinovich NR, Schöning V, Hammann F, Reina G, Sadaba B, Fernández-Alonso M. The effect of early treatment with ivermectin on viral load, symptoms and humoral response in patients with non-severe COVID-19: A pilot, double-blind, placebo-controlled, randomized clinical trial. E ClinicalMedicine 2021; 32 (2021): 1-9. doi: 10.1016/j.eclinm.2020.100720. PMID: 33495752.

Krolewiecki A, Lifschitz A, Moragas M, Travacio M, Valentini R, Alonso DF, Solari R, Tinelli MA, Cimino RO, Álvarez L, Fleitas PE, Ceballos L, Golemba M, Fernández F, Fernández de Oliveira D, Astudillo G, Baeck I, Farina J, Cardama GA, Mangano A, Spitzer E, Gold S, Lanusse C. Antiviral effect of high-dose ivermectin in adults with COVID-19: A proof-of-concept randomized trial. EClinicalMedicine. 2021 Jun 18;37:100959. doi: 10.1016/j.eclinm.2021.100959.

López-Medina E, López P, Hurtado IC, Dávalos DM, Ramirez O, Martínez E, Díazgranados JA, Oñate JM, Chavarriaga H, Herrera S, Parra B, Libreros G, Jaramillo R, Avendaño AC, Toro DF, Torres M, Lesmes MC, Rios CA, Caicedo I. Effect of ivermectin on time to resolution of symptoms among adults with mild COVID-19: A Randomized Clinical Trial. JAMA. 2021 Apr 13;325(14):1426-1435. doi: 10.1001/jama.2021.3071.

Shahbaznejad L, Davoudi A, Eslami G, Markowitz JS, Navaeifar MR, Hosseinzadeh F, Movahedi FS, Rezai MS. Effects of ivermectin in patients with COVID-19: A multicenter, double-blind, randomized, controlled clinical trial. Clin Ther 2021;43(6):1007-1019. doi: 10.1016/j.clinthera.2021.04.007.

Kirti R, Roy R, Pattadar C, Raj R, Agarwal N, Biswas B, Majhi PK, Rai DK, Shyama S, Kumar A, Sarfaraz A. Ivermectin as a potential treatment for mild to moderate COVID-19: A double blind randomized placebo-controlled trial. MedRxiv 21249310. Available from: https:// www.medrxiv.org/content/10.1101/2021.01.05.21249310vl.full.pdf. [Last accessed on 31 Dec 2021].

Bukhari KHS, Asghar A, Perveen N, Hayat A, Mangat SA, Butt KR, Abdullah M, Fatima T, Mustofa A, Iqbal T. Efficacy of COVID-19 patients with mild to moderate disease. MedRxiv 21250840 [Preprint]. Available from: https: //www.medrxiv.org/content/10.1101/2021.02.02.21250840v1. [Last accessed on 31 Dec 2021]

Samaha AA, Mouawia H, Fawaz M, Hassan H, Salami A, Bazzal Aa, Saab Hb, Al-Wakeel M, Al Saabi A, Chouman M, Al Moussawi M, Ayoub H, Raad A, Hajjeh O, Eid AH, Raad H. Effects of a Single Dose of Ivermectin on Viral and Clinical Outcomes in Asymptomatic SARS-CoV-2 Infected Subjects: A Pilot Clinical Trial in Lebanon. Viruses 2021;13(6):1-11. doi:10.3390/v13060989.

Chosidow O, Bernigaud C, Guillemot D, Giraudeau B, Lespine A, Changeux J-P, Bourhy H, Lecuit M, Amoura Z. (2021) Ivermectin as a potential treatment for COVID-19? PLoS Negl Trop Dis 15(6): 1-4. doi:10.1371/journal.pntd.0009446.

Biber A, Mandelboim M, Harmelin G, Lev D, Ram Li, Shaham A, Nemet I, Kliker L, Erster O, Schwartz E. Favorable outcome on viral load and culture viability using Ivermectin in early treatment of non-hospitalized patients with mild COVID-19 – A double-blind, randomized placebo-controlled trial. MedRxiv 21258081. Availablefrom:https://www.medrxiv.org/content/10.1101/2021.05.31.21258081v1. [Last accessed on 16 Aug 2021]

Molento MB. Ivermectin against COVID-19: The unprecedented consequences in Latin America. One Health. 2021 Dec; 13:1-2. doi: 10.1016/j.onehlt.2021.100250. PMID: 33880395.

Kaur H, Shekhar N, Sharma S, Sarma P, Prakash A, Medhi B. Ivermectin as a potential drug for treatment of COVID-19: An in-sync review with clinical and computational attributes. Pharmacol Rep 2021;73(3):736-749. doi: 10.1007/s43440-020-00195-y. PMID: 33389725.

Kriston L. (2013). Dealing with clinical heterogeneity in meta-analysis. Assumptions, methods, interpretation. Int J Methods Psychiatr Res 2013;22(1):1-15. doi: 10.1002/mpr.1377.

Bryant A, Lawrie TA, Dowswell T, Fordham EJ, Mitchell S, Hill S, Tham TC. Ivermectin for Prevention and Treatment of COVID-19 Infection: A Systematic Review, Meta-analysis, and Trial Sequential Analysis to Inform Clinical Guidelines Am J Ther 2021;28 (4): 1-27. doi: 10.1097/MJT.0000000000001402.

Roman YM, Burela PA, Pasupuleti V, Piscoya A, Vidal JE, Hernandez AV. Ivermectin for the treatment of COVID-19: A systematic review and meta-analysis of randomized controlled trials. Clin Infect Dis 2021;1-8. doi: 10.1101/2021.05.21.21257595v2.

Fletcher J. (2007). What is heterogeneity and is it important? BMJ Clinical Research 2021; 334(7584):94-6. doi: 10.1136/bmj.39057.406644.68.

Okumuş N, Demirtürk N, Çetinkaya RA, Güner R, Avcı İY, Orhan S, Konya P, Şaylan B, Karalezli A, Yamanel L, Kayaaslan B, Yılmaz G, Savaşçı Ü, Eser F, Taşkın G. Evaluation of the effectiveness and safety of adding ivermectin to treatment in severe COVID-19 patients. BMC Infect Dis 2021; (2021) 21:1-11. 10.1186/s12879-021-06104-9. PMID: 3394734.

Choudhary R, Sharma AK. Potential use of hydroxychloroquine, ivermectin and azithromycin drugs in fighting COVID-19: trends, scope and relevance. New Microbes New Infect 2020;35 (c):1-4. 10.14744/ejmo.2021.16263. PMID: 32322397.

Popp M, Stegemann M, Metzendorf MI, Gould S, Kranke P, Meybohm P, Skoetz N, Weibel S. Ivermectin for preventing and treating COVID-19. Cochrane Database Syst Rev 2021: ;7(7): 1-159. doi:10.1002/14651858.CD015017.pub2. PMID: 34318930.

Published

07-06-2022

How to Cite

LAKSEMI, D. A. A. S., TUNAS, I. K., WIDYADHARMA, P. E., ARTAWAN, W. G., & SUNDARI, L. P. R. (2022). IVERMECTIN IN THE TREATMENT OF COVID-19 DISEASE: A SYSTEMATIC REVIEW AND META-ANALYSIS. International Journal of Applied Pharmaceutics, 14(4). https://doi.org/10.22159/ijap.2022v14i4.44689

Issue

Section

Review Article(s)

Most read articles by the same author(s)